TSHA · Health care(biological products, (no diagnostic substances)) · 8 years of annual accounts filed with the SEC · latest fiscal year ended 2025-12-31
Signed in, this page also says what this company is inside your own portfolio: its weight, its share of your risk, and what buying or selling some of it would change. Sign in ›
Taysha Gene Therapies, Inc. reported revenue of $9.8 million in fiscal 2025. On the accounting screens, it passes 4 of 8 Piotroski tests, its Altman Z'' of -0.53 is in the distress zone and its Beneish M-score is below the -1.78 line; 2 of the six cross-checks between its statements fire.
Revenue, fiscal 20259.8M
Operating margin-1130.6%gross margin —
Return on invested capital—
Free cash flow after stock pay-107.1M-1096.1% of revenue
Net debt ÷ EBITDANet cash269.7M more cash than debt
Piotroski F-score4/8tests of improvement passed
Share counts are in today's shares. The SEC's filings restate only recent years after a split, so these jumps were read as splits and the older years scaled to match — otherwise per-share figures would compare different units:
2-for-1 before fiscal 2024.
Is it growing?
Revenue and the operating income it turns into. Growth that does not reach operating income is growth bought with margin.
RevenueOperating income
-200M-150M-100M-50M050M
2019
2019
2020Operating income -43.0M
2021Operating income -173.3M
2022Revenue 2.5MOperating income -162.4M
2023Revenue 15.5MOperating income -72.4M
2024Revenue 8.3MOperating income -91.5M
2025Revenue 9.8MOperating income -110.5M
20192019202020212022202320242025
Compound growth a year
3 yrs
5 yrs
7 yrs
Revenue
+57.5%
—
—
Shares
+53.8%
+23.1%
—
Falling shares are buybacks: each remaining share owns more of the company.
Does it earn more than its capital costs?
Margins say how much of each sale is kept; return on invested capital says how much the business earns on the money it needs to operate. Growth only creates value when that return is above the cost of the capital.
Needs a cost of capital, which comes from the valuation below.
Return on equity
-44.1%
Return on assets
-31.7%
Asset turnover
0.03×
Research & development
884.1% of revenue
Overheads (SG&A)
346.5% of revenue
Is the profit cash, and where does the cash go?
Net income is an accounting opinion; free cash flow is what was left in the bank after investing. Stock-based pay does not leave the bank — shareholders pay it through dilution — so it is shown taken off as well.
Net incomeFree cash flowAfter stock-based pay
-200M-150M-100M-50M0
2019
2019
2020Net income -60.0MFree cash flow -30.8MAfter stock-based pay -34.2M
2021Net income -174.5MFree cash flow -132.3MAfter stock-based pay -150.5M
2022Net income -166.0MFree cash flow -109.0MAfter stock-based pay -127.1M
2023Net income -111.6MFree cash flow -76.9MAfter stock-based pay -84.8M
2024Net income -89.3MFree cash flow -81.6MAfter stock-based pay -94.7M
2025Net income -109.0MFree cash flow -93.8MAfter stock-based pay -107.1M
20192019202020212022202320242025
Per share
Earnings per shareFree cash flow per shareDividend per share
-$3-$2-$1$0
2019
2019
2020Earnings per share $-0.53Free cash flow per share $-0.27
2021Earnings per share $-2.32Free cash flow per share $-1.76
2022Earnings per share $-1.89Free cash flow per share $-1.24
2023Earnings per share $-0.48Free cash flow per share $-0.33
2024Earnings per share $-0.36Free cash flow per share $-0.33
2025Earnings per share $-0.34Free cash flow per share $-0.29
20192019202020212022202320242025
Shares outstanding
Diluted shares
0100M200M300M400M
2019
2019Diluted shares 32.7M
2020Diluted shares 113.3M
2021Diluted shares 75.3M
2022Diluted shares 87.9M
2023Diluted shares 232.2M
2024Diluted shares 250.1M
2025Diluted shares 319.7M
20192019202020212022202320242025
Debt and liquidity
Debt is not bad in itself; debt the business cannot service in a bad year is. Net debt is debt minus cash, and below zero the company holds more cash than it owes.
Net debt
-300M-200M-100M0
2019
2019
2020
2021Net debt -111.9M
2022Net debt -49.9M
2023Net debt -103.4M
2024Net debt -95.1M
2025Net debt -269.7M
20192019202020212022202320242025
Net debt ÷ EBITDA
2.5×
Interest coverage
-1754× operating income ÷ interest
Current ratio
12.23 current assets ÷ current liabilities
Cash conversion cycle
—
Three classic screens of the accounts
Each asks a different question of the same statements — is it improving, does it look like a company heading for distress, do the accounts resemble ones that were manipulated. None is a verdict; each shows what moves it.
Piotroski F-score
Is the business improving? Nine yes-or-no tests, this year against last.
4of 8 tests passed
✕ProfitableReturn on assets above zerofailed
✕Cash from operationsOperating cash flow above zerofailed
✓Profitability improvedReturn on assets higher than a year beforepassed
✓Profit backed by cashOperating cash flow above net income (low accruals)passed
✓Less long-term debtLong-term debt as a share of assets fellpassed
✓More liquidCurrent ratio higher than a year beforepassed
✕No new sharesShare count did not growfailed
–Better gross marginGross margin higher than a year before — not reportedno data
✕Sells more per assetAsset turnover higher than a year beforefailed
Where it misleads: it measures change, not level. An excellent business that stood still for a year scores low; a poor one recovering from a disaster scores high.
Altman Z''-score
Does the balance sheet look like those of companies that went bankrupt?
-0.53distress zone
1.12.6
Working capital ÷ assets 0.87 × 6.56+5.70
Retained earnings ÷ assets -2.07 × 3.26-6.75
Operating income ÷ assets -0.32 × 6.72-2.16
Equity ÷ liabilities 2.56 × 1.05+2.69
Where it misleads: buybacks. A company that returns so much cash that its equity turns small or negative sinks the last two ratios without being anywhere near bankruptcy. Banks and insurers do not fit the model at all.
Beneish M-score
Do the accounts resemble those of companies that manipulated their earnings?
-2.58below the -1.78 line
-1.78
Receivables vs sales 1.00 (not reported, set to 1)+0.92
Gross margin slipping 1.00 (not reported, set to 1)+0.53
Soft assets 0.52+0.21
Sales growth 1.17+1.05
Slower depreciation 0.98+0.11
Overheads vs sales 1.00-0.17
Profit not in cash -0.05-0.22
Leverage rising 0.51-0.17
Where it misleads: fast growth and acquisitions. Sales growth carries a heavy weight, so a company growing 50% a year scores like a suspect without having done anything. It is a screen from a 1999 study, not an accusation.
Where the statements disagree
Cross-checks between the income statement, the balance sheet and the cash flow for the latest year, each with the benign reading and the worrying one.
Reported profit comfortably exceeds the cash generated (-109M against -93M).
Benign
Growth consuming working capital, or the seasonality of the year-end.
Worrying
Profit held up by accounting entries that do not turn into money.
Capital spending (1M) is well below depreciation (1M).
Benign
Mature assets, or a business that has become less capital-intensive.
Worrying
Under-investing: today's profit is being held up by consuming tomorrow's capacity.
What is it worth, under which assumptions?
A company is worth the cash it will generate, brought back to today. This model projects revenue with growth that fades over the years, applies a free cash flow margin, and discounts the result at the cost of capital. Every assumption says where it came from, and all of them can be changed.
The SEC accounts lack the lines needed for revenue, free cash flow or the share count, so there is no DCF for this company.
What it has filed lately
The last twelve months at the SEC, most important first: annual and quarterly reports, events, large holders and insiders.
Every Form 4 filed in the last twelve months, read line by line: 6 filings by 5 people. Open-market purchases and sales are counted apart from awards, option exercises and shares withheld for taxes.
Bought on the open market—none in the period
Sold on the open market$2.1M2 sale(s) by 1 insider(s)
Under pre-arranged plans100%of the sales followed a 10b5-1 plan set months earlier
A Form 4 says what happened, when, how many shares and at what price. It does not say why: a sale can be diversification, a tax bill or a plan fixed months earlier, and an award is pay, not a purchase. Nothing here is a reason to buy or sell anything.
Which large funds report holding it
From the Form 13F of the 28 institutions followed on this site, as of the end of their last reported quarter. A 13F is filed up to 45 days later and shows only long positions in US-listed shares.
Accounts from the company's own SEC filings; lines some companies do not report are shown as a dash rather than estimated. The risk-free rate is the 10-year US Treasury yield. A DCF is a way of making assumptions explicit, not a forecast: it states what the company would be worth if the assumptions held. The scores are screens that point where to look, not verdicts. Nothing here is a recommendation to buy or sell.
